Azitra, Inc. to Present at the BIO CEO & Investor Conference

Company Overview - Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology [2] - The company's lead product, ATR-12, is designed to treat Netherton syndrome, a rare chronic skin disease with no approved treatment options [2] - ATR-12 is currently being evaluated in a Phase 1b clinical trial in adult patients with Netherton syndrome [2] - Azitra's second product, ATR-04, targets EGFR inhibitor associated rash, which affects approximately 150,000 people in the U.S. [2] - Azitra has received Fast Track designation from the FDA for ATR-04 [2] - The company utilizes a proprietary platform of engineered proteins and topical live biotherapeutic products, supported by a microbial library of around 1,500 bacterial strains [2] Upcoming Events - Azitra will present at the BIO CEO & Investor Conference on February 10, 2025, at 3:45 p.m. ET in New York City [1] - The presentation will be led by Travis Whitfill, Chief Operating Officer, and will include one-on-one meetings with registered investors and potential partners [1]